• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cigna To $335? Plus This Analyst Slashes PT On Six Flags Entertainment By 25%

    11/8/22 6:19:30 AM ET
    $ACA
    $CI
    $KRYS
    $NSSC
    Metal Fabrications
    Industrials
    Medical Specialities
    Health Care
    Get the next $ACA alert in real time by email

     


    • SVB Leerink raised the price target on Cigna Corporation (NYSE:CI) from $305 to $335. Cigna shares rose 0.7% to close at $324.37 on Monday.

    • Jefferies lowered Six Flags Entertainment Corporation (NYSE:SIX) price target from $32 to $24. Six Flags Entertainment shares fell 0.2% to close at $21.16 on Monday.

    • RBC Capital cut Q2 Holdings, Inc. (NYSE:QTWO) price target from $38 to $32. Q2 Holdings shares fell 9.2% to $24.00 in pre-market trading.

    • Stephens & Co. cut the price target on Arcosa, Inc. (NYSE:ACA) from $75 to $65. Arcosa shares fell 0.9% to $58.76 in pre-market trading.

    • Piper Sandler cut the price target for Oyster Point Pharma, Inc. (NASDAQ:OYST) from $15 to $11. Oyster Point Pharma shares fell 1.1% to $11.44 in pre-market trading.

    • Needham boosted the price target on Napco Security Technologies, Inc. (NASDAQ:NSSC) from $33 to $34. Napco Security Technologies shares rose 14.2% to close at $28.20 on Monday.

    • Chardan Capital raised the price target for Krystal Biotech, Inc. (NASDAQ:KRYS) from $130 to $133. Krystal Biotech shares gained 6.6% to close at $78.05 on Monday.


    •  

     

     

     

    Get the next $ACA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACA
    $CI
    $KRYS
    $NSSC

    CompanyDatePrice TargetRatingAnalyst
    Q2 Holdings Inc.
    $QTWO
    2/3/2026$82.00Neutral → Buy
    DA Davidson
    Krystal Biotech Inc.
    $KRYS
    1/6/2026$309.00Neutral → Buy
    Citigroup
    NAPCO Security Technologies Inc.
    $NSSC
    11/4/2025$50.00Hold → Buy
    TD Cowen
    The Cigna Group
    $CI
    10/14/2025$370.00Buy
    Goldman
    NAPCO Security Technologies Inc.
    $NSSC
    8/26/2025$39.00Hold → Buy
    Lake Street
    NAPCO Security Technologies Inc.
    $NSSC
    8/26/2025$40.00Hold → Buy
    Craig Hallum
    NAPCO Security Technologies Inc.
    $NSSC
    7/10/2025$39.00Outperform
    Mizuho
    Q2 Holdings Inc.
    $QTWO
    6/18/2025$115.00Overweight
    Analyst
    More analyst ratings

    $ACA
    $CI
    $KRYS
    $NSSC
    SEC Filings

    View All

    SEC Form 10-K filed by Q2 Holdings Inc.

    10-K - Q2 Holdings, Inc. (0001410384) (Filer)

    2/11/26 5:02:54 PM ET
    $QTWO
    Computer Software: Prepackaged Software
    Technology

    Q2 Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Q2 Holdings, Inc. (0001410384) (Filer)

    2/11/26 4:19:55 PM ET
    $QTWO
    Computer Software: Prepackaged Software
    Technology

    SEC Form 144 filed by The Cigna Group

    144 - Cigna Group (0001739940) (Subject)

    2/6/26 2:05:58 PM ET
    $CI
    Medical Specialities
    Health Care

    $ACA
    $CI
    $KRYS
    $NSSC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evernorth Health Services Teams Up with Direct Relief To Deliver Critical Medications to Communities Impacted by Disasters

    Evernorth's home delivery pharmacy donated more than 41,000 prescription medications to Direct Relief for initial supply Collaboration creates a scalable, replicable model for pharmacies to support disaster preparedness and future humanitarian responseBLOOMFIELD, Conn., Feb. 12, 2026 /PRNewswire/ -- Evernorth, the health services division of The Cigna Group (NYSE:CI), has partnered with Direct Relief to donate more than 41,000 lifesaving prescription medications for rapid deployment during natural disasters and other emergencies. Through this collaboration, Evernorth's Express Scripts Pharmacy has created a first–of–its–kind donation pathway that enables humanitarian organizations to source

    2/12/26 9:00:00 AM ET
    $CI
    Medical Specialities
    Health Care

    Q2 Holdings, Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results

    Q2 Holdings, Inc. (NYSE:QTWO), a leading provider of digital transformation solutions for financial services, today announced results for its fourth quarter and full year ending December 31, 2025. GAAP Results for the Fourth Quarter and Full-Year 2025 Revenue for the fourth quarter of $208.2 million, up 14 percent year-over-year and up 3 percent from the third quarter of 2025. Full-year 2025 revenue of $794.8 million, up 14 percent year-over-year. GAAP gross margin for the fourth quarter of 55.4 percent, up from 52.6 percent for the prior-year quarter and up from 54.0 percent for the third quarter of 2025. GAAP gross margin for full-year 2025 of 54.1 percent, up from 50.9 percent fo

    2/11/26 4:15:00 PM ET
    $QTWO
    Computer Software: Prepackaged Software
    Technology

    Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

    PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Tuesday, February 17, 2026, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53598. For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company's websi

    2/10/26 8:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACA
    $CI
    $KRYS
    $NSSC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Q2 Holdings upgraded by DA Davidson with a new price target

    DA Davidson upgraded Q2 Holdings from Neutral to Buy and set a new price target of $82.00

    2/3/26 6:50:55 AM ET
    $QTWO
    Computer Software: Prepackaged Software
    Technology

    Krystal Biotech upgraded by Citigroup with a new price target

    Citigroup upgraded Krystal Biotech from Neutral to Buy and set a new price target of $309.00

    1/6/26 8:26:47 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Napco Security Systems upgraded by TD Cowen with a new price target

    TD Cowen upgraded Napco Security Systems from Hold to Buy and set a new price target of $50.00

    11/4/25 7:20:09 AM ET
    $NSSC
    Telecommunications Equipment
    Telecommunications

    $ACA
    $CI
    $KRYS
    $NSSC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Romano Kathryn exercised 12,500 shares at a strike of $63.55, sold $3,401,705 worth of shares (12,500 units at $272.14) and gifted 750 shares, decreasing direct ownership by 4% to 18,568 units (SEC Form 4)

    4 - Krystal Biotech, Inc. (0001711279) (Issuer)

    2/11/26 7:08:54 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO, Chairman of Board, Secy Soloway Richard exercised 108,000 shares at a strike of $22.82 and covered exercise/tax liability with 82,052 shares, increasing direct ownership by 2% to 1,281,958 units (SEC Form 4)

    4 - NAPCO SECURITY TECHNOLOGIES, INC (0000069633) (Issuer)

    2/11/26 4:10:56 PM ET
    $NSSC
    Telecommunications Equipment
    Telecommunications

    CEO, Chairman of Board, Secy Soloway Richard sold $6,411,000 worth of shares (150,000 units at $42.74), decreasing direct ownership by 11% to 1,256,010 units (SEC Form 4)

    4 - NAPCO SECURITY TECHNOLOGIES, INC (0000069633) (Issuer)

    2/6/26 4:14:22 PM ET
    $NSSC
    Telecommunications Equipment
    Telecommunications

    $ACA
    $CI
    $KRYS
    $NSSC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 19, 2023 - FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

    For Immediate Release: May 19, 2023 Today, the U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.  “Vyjuvek is the first FDA-approved gene therapy treatment for DEB, a

    5/19/23 1:48:20 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for TYRVAYA issued to OYSTER POINT PHARMA INC

    Submission status for OYSTER POINT PHARMA INC's drug TYRVAYA (ORIG-1) with active ingredient VARENICLINE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 213978, Application Classification: Type 3 - New Dosage Form

    10/19/21 7:27:01 PM ET
    $OYST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACA
    $CI
    $KRYS
    $NSSC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman & CEO Cordani David bought $999,916 worth of shares (4,134 units at $241.88) (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    11/3/25 2:47:56 PM ET
    $CI
    Medical Specialities
    Health Care

    President & CEO Carrillo Antonio bought $498,438 worth of shares (6,345 units at $78.56), increasing direct ownership by 1% to 433,283 units (SEC Form 4)

    4 - Arcosa, Inc. (0001739445) (Issuer)

    3/10/25 5:57:52 PM ET
    $ACA
    Metal Fabrications
    Industrials

    Director Best Rhys J bought $119,752 worth of shares (1,500 units at $79.83), increasing direct ownership by 3% to 58,195 units (SEC Form 4)

    4 - Arcosa, Inc. (0001739445) (Issuer)

    3/5/25 5:11:50 PM ET
    $ACA
    Metal Fabrications
    Industrials

    $ACA
    $CI
    $KRYS
    $NSSC
    Financials

    Live finance-specific insights

    View All

    Q2 Holdings, Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results

    Q2 Holdings, Inc. (NYSE:QTWO), a leading provider of digital transformation solutions for financial services, today announced results for its fourth quarter and full year ending December 31, 2025. GAAP Results for the Fourth Quarter and Full-Year 2025 Revenue for the fourth quarter of $208.2 million, up 14 percent year-over-year and up 3 percent from the third quarter of 2025. Full-year 2025 revenue of $794.8 million, up 14 percent year-over-year. GAAP gross margin for the fourth quarter of 55.4 percent, up from 52.6 percent for the prior-year quarter and up from 54.0 percent for the third quarter of 2025. GAAP gross margin for full-year 2025 of 54.1 percent, up from 50.9 percent fo

    2/11/26 4:15:00 PM ET
    $QTWO
    Computer Software: Prepackaged Software
    Technology

    Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

    PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Tuesday, February 17, 2026, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53598. For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company's websi

    2/10/26 8:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Cigna Group Reports Strong Fourth Quarter and Full Year 2025 Results, Establishes 2026 Outlook and Increases Dividend

    Total revenues for 2025 increased 11% to $274.9 billionShareholders' net income for 2025 was $6.0 billion, or $22.18 per shareAdjusted income from operations1 for 2025 was $8.0 billion, or $29.84 per share2026 adjusted income from operations1 is projected to be at least $7.950 billion, or at least $30.25 per share2Board of Directors declared an increase in the quarterly dividend to $1.56 per shareBLOOMFIELD, Conn., Feb. 5, 2026 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) today reported 2025 results, underscoring operational discipline and the strength of its complimentary portfolio of global health businesses.

    2/5/26 6:00:00 AM ET
    $CI
    Medical Specialities
    Health Care

    $ACA
    $CI
    $KRYS
    $NSSC
    Leadership Updates

    Live Leadership Updates

    View All

    VINCENT COUNTRY SAFE ZONE ACTIVITY DAY PRESENTED BY CIGNA HEALTHCARE DELIVERS SUPER BOWL WEEK FUN, NFL FLAG FOOTBALL, AND WELLNESS TO OAKLAND STUDENTS

    Corporate, Nonprofit, and Philanthropic Partners Collaborated to Provide Transformative Experiences and Lasting Resources at Burckhalter Elementary School OAKLAND, Calif., Feb. 3, 2026 /PRNewswire/ -- Vincent Country Safe Zone Activity Day Presented by Cigna Healthcare, a flagship initiative of Love Thy Neighbor CDC co-founded by NFL Executive and Legend Troy Vincent, Sr. and his wife, author and chef Tommi A. Vincent, took place Tuesday, February 3, at Burckhalter Elementary School in Oakland, CA. The ninth annual event, themed Dreams Grow Here, delivered a full day of fun, food, wellness, and engaging sports activities, including NFL FLAG, for more than 200 Pre-K through fifth-grade studen

    2/3/26 8:17:00 PM ET
    $CI
    Medical Specialities
    Health Care

    Austin FC and Q2 Announce the 2025 "Q-mmunity Gives" Grant Recipients; $150,000 Awarded to Local Nonprofits

    Breakthrough Central Texas, Marbridge Foundation, and Saint Louise House named recipients of the fifth annual Q-mmunity Gives grant program Austin FC and Q2 Holdings, Inc. today announced the three (3) recipients of the 2025 Q-mmunity Gives grant program. Local nonprofit organizations Breakthrough Central Texas, Marbridge Foundation, and Saint Louise House will each receive a $50,000 grant to focus on their respective missions. "We'd like to congratulate Breakthrough Central Texas, Marbridge Foundation, and Saint Louise House on being named this year's grant recipients," said Austin FC President Andy Loughnane. "We are extremely proud to work alongside our partners at Q2 for a fifth con

    11/14/25 10:00:00 AM ET
    $QTWO
    Computer Software: Prepackaged Software
    Technology

    Land & Buildings Issues Letter Detailing Why Now Is the Time to Finally Unlock Six Flags' Substantial Trapped Real Estate Value

    Believes Monetizing Company's Real Estate While Driving Operational Turnaround in Parallel Could Result in Massive Upside to Current Share Price Confident FUN Real Estate Could Attract Multiple Bidders and Sell for Up to $6 Billion; REIT Spin-Out is More Viable Than Ever Given Increased Scale Following Merger with Cedar Fair Views Combination of Real Estate Monetization and Turnaround as Best Pathway to Company Beginning to Trade at Fair Value After Years of Underperformance Today, Land & Buildings Investment Management, LLC (together with its affiliates, "Land & Buildings," "L&B," "us" or "we"), a substantial shareholder of Six Flags Entertainment Corporation (NYSE: FUN) ("Six Flags,

    9/26/25 7:00:00 AM ET
    $FUN
    $SIX
    $VICI
    Services-Misc. Amusement & Recreation
    Consumer Discretionary
    Real Estate Investment Trusts
    Real Estate

    $ACA
    $CI
    $KRYS
    $NSSC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

    SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)

    11/14/24 9:00:58 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by NAPCO Security Technologies Inc.

    SC 13G - NAPCO SECURITY TECHNOLOGIES, INC (0000069633) (Subject)

    11/12/24 10:32:14 AM ET
    $NSSC
    Telecommunications Equipment
    Telecommunications

    Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

    SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)

    11/12/24 10:32:12 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care